Edoxaban tosylate monohydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314259

CAS#: 1229194-11-9 (tosylate hydrate)

Description: Edoxaban (INN, codenamed DU-176b, trade name Lixiana) is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.

Price and Availability


USD 150
USD 750
USD 2650
USD 6650

USD 250
USD 1250
USD 3650
USD 9650

USD 450
USD 1750
USD 4650
Ask price

Edoxaban tosylate monohydrate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 314259
Name: Edoxaban tosylate monohydrate
CAS#: 1229194-11-9 (tosylate hydrate)
Chemical Formula: C31H40ClN7O8S2
Exact Mass:
Molecular Weight: 738.272
Elemental Analysis: C, 50.43; H, 5.46; Cl, 4.80; N, 13.28; O, 17.34; S, 8.69

Synonym: DU176b; DU-176b; DU 176b; Edoxaban; Edoxaban tosylate monohydrate, trade name Lixiana.

IUPAC/Chemical Name: N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate


InChi Code: InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1

SMILES Code: O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.CC5=CC=C(S(=O)(O)=O)C=C5.[H]O[H]

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Related CAS#
1229194-11-9 (Edoxaban tosylate hydrate);
480449-70-5 (Edoxaban free base).


1: Traynor K. Edoxaban approved for embolism prevention. Am J Health Syst Pharm. 2015 Feb 15;72(4):258. doi: 10.2146/news150011. PubMed PMID: 25631826.

2: Marlu R, Polack B, Pernod G. Ex vivo reversal of the anticoagulant effects of edoxaban - comments on the study by Halim et al. Thromb Res. 2015 Jan 7. pii: S0049-3848(15)00004-3. doi: 10.1016/j.thromres.2015.01.002. [Epub ahead of print] PubMed PMID: 25628140.

3: De Caterina R. [Clinical implications of edoxaban in the current scenario of oral anticoagulants]. G Ital Cardiol (Rome). 2014 Dec;15(12):27-9. doi: 10.1714/1744.18990. Italian. PubMed PMID: 25621575.

4: Di Pasquale G, Riva L. [Edoxaban for the treatment of atrial fibrillation: the ENGAGE AF-TIMI 48 study]. G Ital Cardiol (Rome). 2014 Dec;15(12):22-6. doi: 10.1714/1744.18988. Italian. PubMed PMID: 25621574.

5: Andreotti F. [Molecular structure and pharmacology of edoxaban]. G Ital Cardiol (Rome). 2014 Dec;15(12):11-6. doi: 10.1714/1744.18984. Italian. PubMed PMID: 25621572.

6: Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol. 2015 Feb;143(2):241-7. doi: 10.1309/AJCPQ2NJD3PXFTUG. PubMed PMID: 25596250.

7: Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis. Thromb Haemost. 2015 Jan 8;113(3). [Epub ahead of print] PubMed PMID: 25566930.

8: Spanos K, Giannoukas AD. Re: 'Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'. Eur J Vasc Endovasc Surg. 2014 Dec 30. pii: S1078-5884(14)00655-8. doi: 10.1016/j.ejvs.2014.11.019. [Epub ahead of print] PubMed PMID: 25556084.

9: Kakkos SK, Kirkilesis GI, Tsolakis IA. Response to 'Re: Kakkos et al. Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'. Eur J Vasc Endovasc Surg. 2014 Dec 30. pii: S1078-5884(14)00656-X. doi: 10.1016/j.ejvs.2014.12.007. [Epub ahead of print] PubMed PMID: 25556083.

10: Herzog E, Kaspereit F, Krege W, Doerr B, Mueller-Cohrs J, Pragst I, Morishima Y, Dickneite G. Effective Reversal of Edoxaban-associated Bleeding with Four-factor Prothrombin Complex Concentrate in a Rabbit Model of Acute Hemorrhage. Anesthesiology. 2015 Feb;122(2):387-98. doi: 10.1097/ALN.0000000000000520. PubMed PMID: 25419685.